ERBB2 and breast cancer: CCK8 assay showed that trastuzumab-sensitive effect after FAK silencing could be partially restored by over-expressing circCDYL2 in both P-BT474 and P-SK-BR-3 cells (Fig. 6G), indicating that circCDYL2 promoted drug resistance of HER2+ BC cells via FAK.